Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(03): 203-206
DOI: 10.4103/0971-5851.142035
REVIEW ARTICLE

Oligometastatic breast cancer: A mini review

Sameer Rastogi
Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
,
Seema Gulia
Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
,
Jyoti Bajpai
Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
,
Jaya Ghosh
Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
,
Sudeep Gupta
Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

With few exceptions such as germ cell tumors, trophoblastic neoplasms and colonic cancers, metastatic solid tumors are considered largely incurable. It is increasingly appreciated that oligometaststic cancer differs from multi-metastatic disease in prognosis and survival. Oligometastatic breast cancer (OMBC) is, therefore, sometimes considered as an intermediate biological state between localized and widely metastatic disease. There is no strict definition of OMBC with studies using different criteria. Treatment of OMBC is still controversial in view of sparse data that is retrospective. However, there is an increasing shift toward individualized, multidisciplinary management of OMBC with the intent to cure some patients. This article will concisely review the subject of OMBC from points of view of biology and practical management recommendations.

Keywords

Oligometastastasis - breast cancer - cure


Publication History

Article published online:
19 July 2021

© 2014. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 2008;100:1780-91.
  • 2 Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-103.
  • 3 Jain SK, Dorn PL, Chmura SJ, Weichselbaum RR. Incidence and implications of oligometastatic breast cancer. J Clin Oncol 2012;30. [Suppl; abstr e11512].
  • 4 Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, et al. Combined-modality treatment forisolated recurrences of breast carcinoma: Update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 2005;104:1158-71.
  • 5 Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, et al. Possible clinical cure of metastatic breast cancer: Lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer 2012;19:218-37.
  • 6 Gupta GP, Massagué J. Cancer metastasis: Building a framework. Cell 2006;127:679-95.
  • 7 Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893-5.
  • 8 Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 2001;7:630-6.
  • 9 Shindo-Okada N, Takeuchi K, Nagamachi Y. Establishment of cell lines with high-and low-metastatic potential from PC-14 human lung adenocarcinoma. Jpn J Cancer Res 2001;92:174-83.
  • 10 Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
  • 11 Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: A subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013;31:1384-90.
  • 12 Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study. Lancet 1999;354:197-202.
  • 13 Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205.
  • 14 Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979;39:1552-62.
  • 15 Farquhar C, Basser R, Marjoribanks J, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. The Cochrane Database of Systematic Reviews 2003; CD003139. DOI: 10.1002/14651858.
  • 16 Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials. J Clin Oncol 2011;29:3214-23.
  • 17 Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002;20:707-18.
  • 18 Bojko P, Welt A, Schleucher R, Borquez D, Scheulen ME, Vanhoefer U, et al. High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplant 2004;34:637-43.
  • 19 Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured? J Natl Cancer Inst 2010;102:456-63.
  • 20 Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989;49:1996-2001.
  • 21 Olson JA Jr, Marcom PK. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. Ann Surg 2008;247:739-40.
  • 22 Badwe R, Parmar V, Hawaldar R, Nair N, Kaushik R, Siddique S, et al. Surgical removal of primary breast tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial. [Abstract S2-02]. Presented at: 2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, TX.
  • 23 Friedel G, Pastorino U, Ginsberg RJ, Goldstraw P, Johnston M, Pass H, et al. Results of lung metastasectomy from breast cancer: Prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg 2002;22:335-44.
  • 24 Rena O, Papalia E, Ruffini E, Filosso PL, Oliaro A, Maggi G, et al. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol 2007;33:546-50.
  • 25 Welter S, Jacobs J, Krbek T, Tötsch M, Stamatis G. Pulmonary metastases of breast cancer. When is resection indicated? Eur J Cardiothorac Surg 2008;34:1228-34.
  • 26 Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, et al. First isolated locoregional recurrence following mastectomy for breast cancer: Results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994;12:2071-7.
  • 27 Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial. Lancet Oncol 2014;15:156-63.